retatrutide clinical trial Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more at our link in bio Retatrutide for weight loss: Study

In the past decades, several groups have found that drugs that harmine and other dual specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors are able to induce proliferation of human -cell and increase islet mass in vitro and vivo, and its pro-proliferative effects primarily operate via translocation of nuclear factor of activated T-cells (NFAT) transcription factors to the nucleus, with the consequent transactivation of cyclins such as cyclin A, CDKs such as CDK1, and repression of CDK-inhibitors such as p15 INK4 , p21 CIP1 , and p57 KIP2 [42, 43]

These deals could encourage expansion of GLP-1 coverage, said LDI Senior Fellow Matthew Klebanoff

Which medication is right for you

Clinician-Guided Weight Loss Options Access oral or injectable medications with licensed clinician oversight to pursue safe, personalized, and sustainable weight loss

I.BnemannM.KraselC.KarimianT.et al (2022)

Both medications are FDA approved for Type 2 diabetes and, given their profound impact on weight loss, often prescribed off-label for obesity